Search - tctmd.com

Displaying 1 - 20 of 95

Sort: Relevancy | Date

Presentation TCT 2020

Five-Year Follow-Up from the PARTNER 2 Aortic Valve-in-Valve Registries: Clinical Outcomes, Valve Function, and Durability

Presenter: Rebecca T. Hahn

October 17, 2020

Presentation TVT 2020

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Presenter: Susheel K. Kodali

June 21, 2020

Presentation Cardiovascular Interventions 2019

Show me the Data: Key Clinical Trials of 2019

Presenter: Ehtisham Mahmud

November 01, 2019

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

Presentation CIT 2019

PARTNER 3 and TAVR Trials

Presenter: Rebecca T. Hahn

March 28, 2019

Presentation ACC 2019

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Presenter: Martin B. Leon

March 17, 2019

Presentation TCT 2018

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Presenter: John G. Webb

September 23, 2018

Presentation EuroPCR 2018

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Presenter: E. Murat Tuzcu

May 25, 2018

Presentation TVT 2017

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

Presenter: Martin B. Leon, Hendrik Treede, Philippe Pibarot

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation

Timing, Risk Factors, Outcomes of Stroke, TIA after TAVR: PARTNER Trial

Presenter: Samir Kapadia

September 12, 2016

Presentation TVT 2016

PARTNER Echocardiography Observations on Valve Durability

Presenter: Rebecca T. Hahn

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

Presentation

A-fib Associated With Increased Mortality in Patients Undergoing TAVR: PARTNER Analysis

Presenter: Angelo Biviano

January 07, 2016

Presentation

Temporal Trends in QoL Outcomes After Transapical TAVR: PARTNER Substudy

Presenter: H. Gada

June 12, 2015

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

Presentation

PARTNER: Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After TAVR

Presenter: T.M. Nazif

January 19, 2015

Advertisement

Five-Year Follow-Up from the PARTNER 2 Aortic Valve-in-Valve Registries: Clinical Outcomes, Valve Function, and Durability

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Show me the Data: Key Clinical Trials of 2019

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

PARTNER 3 and TAVR Trials

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Timing, Risk Factors, Outcomes of Stroke, TIA after TAVR: PARTNER Trial

PARTNER Echocardiography Observations on Valve Durability

Study Design for the PARTNER 3 Low-Risk Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

A-fib Associated With Increased Mortality in Patients Undergoing TAVR: PARTNER Analysis

Temporal Trends in QoL Outcomes After Transapical TAVR: PARTNER Substudy

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

PARTNER: Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content